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In the current issue of the Journal of Epidemiology, Mishiro
et al1 present a very careful and detailed cost estimation for a
molecular epidemiology cohort study in a model region of
Japan. Their approach and key points can be extended to other
studies worldwide in order to rationalize planning and costs
of molecular epidemiology cohort studies. Of particular
interest—though subject to a range of errors due to
unexpected events—is their careful allocation and deﬁnition
of time requested for each unit of personnel, since personnel
costs account for the major proportion of the total costs of
epidemiological studies.
Such a detailed deﬁnition of costs may well become a
benchmark for other epidemiology studies worldwide. There
are two aspects, however, that require additional attention.
First, the new cohort described by Mishiro et al,1 which
includes 7400 subjects, is relatively small for the subsequent
analysis of most of its possible outcomes, despite its
comprehensive and innovative data collection compared to
cohorts deﬁned in the 1980s and 1990s.2,3 Thus, this dataset
will inevitably need to be integrated with data from other
cohort studies from Japan and other areas of the world; a
similar project was recently developed within a network of
cohort studies that included 23 European and 3 non-European
studies (the Consortium of Health and Ageing), which includes
over 680 000 elderly.4 The same line of reasoning applies to
the potential integration of some data from this project for the
design of nested case-control studies in related consortia.5
Such integration has to be considered in the study design
and planning phases and may have some—though partial and
modest—inﬂuence on deﬁnition of cost estimations.
An additional issue in planning a molecular epidemiology
cohort study is the deﬁnition of the biological material to be
stocked and subsequently analyzed, as well as the modalities
of its stocking, in order to assure greater and optimal
utilization in the long term, an element which may not
necessarily be easy to deﬁne in advance. This correlates with
the deﬁnition of epidemiological information to be collected,
which again has implications for study costs.
In addition, starting from planning and cost estimation of a
cohort study, the burden of its follow-up should be considered
in advance as an important future cost element. Record linkage
across several databases now offers important potentialities
for optimizing follow-up at low cost,6,7 but this may not cover
the practical totality of subjects to be followed (ie, generally
over 95% of the original cohort). Consequently, active follow-
up may be required,8 and this may appreciably inﬂuence
subsequent costs of the study. Thus, the burden of follow-up
should also be considered and optimized in study planning.
Despite these limitations, the paper by Mishiro et al1
constitutes an important exercise towards cost estimation of
a baseline survey for a cohort study that includes biological
and molecular information. Therefore, this manuscript should
be regarded as an example for practical deﬁnition and method-
ology optimization of future studies in other populations.
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